Onko Pharmaceuticals has first taken its place in pharmaceutical sector in 1987 by introducing blood derivative products in Turkey, and by getting distribution on exclusive base from the best known pharmaceutical companies of Europe. Until now Onko keeps on serving in this field by still being the leading importer of blood products through satisfying the high need of blood products in Turkey on a large scale.
In 1995, Kocsel Pharmaceuticals has joined to the family with hepatitis B vaccine and biological product group. In subsequent years, it has undertaken the mission of providing a part of Turkeys vaccine needs, which has occurred due to the attendance of Turkey to the global immunization program. After one year, as a result of success in its own sector; Onko & Kocsel Pharmaceuticals, has achieved to extend its horizon in the pharmaceutical sector by setting up an oncology business unit.
In 2002, Onko & Kocsel Pharmaceuticals took the first step on manufacturing by taking over manufacturing licenses from Roche Pharmaceuticals. This brought a new vision to Onko & Kocsel Pharmaceuticals.
Onko & Kocsel Pharmaceuticals has achieved to reflect its fast success also to its organizational structure and adapted Total Quality System to mantain professional management.
Onko & Kocsel Pharmaceuticals focused on adding new products to its mainly Oncology, Radiation Oncology, Hematology, Neurology, Infection diseases, Urology, Physical Medicine & Rehabilitation, Orthopedics, Rheumatology, Immunology, Dermatology and Internal Medicine portfolio year after year. With its dedicated staff and well organized and positioned structure Onko & Kocsel Pharmaceuticals has reached its target consumers throughout Turkey. In the medical marketing; strong professional customer-focused relations, effective meeting organizations, effective communication skills, power of investment and clinically-focused scientific approaches have constituted its vision. Onko & Kocsel Pharmaceuticals plays a significant role with well-educated, professionally trained, experienced, dynamic and result oriented sale force.
Onko & Kocsel keeps showing promising rise by signing new business agreements with strong companies and expanding its product portfolio in the light of innovative and stable development. Onko & Kocsel Pharmaceuticals looks ahead with confidence with an experience more than 20 years in the Pharmaceutical market.
Contact Details Onko ilaç San. ve Tic. A.Ş.
Koşuyolu Cad. No:34 34718 Koşuyolu Kadıköy – İstanbul / Türkiye
Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over…
Consumer healthcare products manufacturer Winalite is working to penetrate the Turkish market, but with regulations complicating bringing their portfolio from China, general manager Arafat Yadigar is looking to develop a…
Ozgur Tomruk, J&J’s Managing Director for Global Surgery talks about Turkey’s importance for the company, the priorities they have set, J&J’s commitment to quality and his ambition for the company’s…
Nil Tunaşar, managing partner of Transorient, discusses significance of tracking performance metrics among 3PL providers, the organization’s technology overhaul, and also highlights the type of logistics solutions encompassed under Transorient’s…
Matthias Diewald (MD) and Asli Volkan (AV) elaborate on HELM Kimya’s longstanding presence within Turkey and the type of market opportunities available for co-development and contract manufacturing. They also explain the…
Haluk Ataoglu, academic turned founder of Matriks Biotek®, talks about his aspirations for his company and the Turkish R&D landscape as well as how to penetrate the global pharmaceutical market…
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
BMS Turkey’s new general manager discusses Opdivo (nivolumab) their revolutionary new product for squamous non-small cell lung cancer, their registry of 1200 patients in Turkey with melanoma, potential developments in pharmaceutical…
Multinational R&D investment in Turkey, particularly investment in clinical trials, has been quite limited relative to the size of the Turkish pharmaceutical market. Turkish R&D spending amounted to just 0.95…
Over the past six years, Turkey has consistently lowered its drugs prices and guided its companies to greater efficiency. “Reference prices in Turkey are constructed from the lowest price in…
In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning…
Recep Altekin, the general manager of MT Sağlik – market leader in Turkey for blood glucose monitoring systems and diabetes test strips by volume – tells PharmaBoardroom about his company’s impact…
AstraZeneca’s Country President for Turkey discusses their efforts to build scientific leadership in Turkey in line with their global strategy and her hopes for the market access and public-private…